HISUN(SH:600267) Zheng Quan Shi Bao Wang·2025-10-19 09:17Core Viewpoint - The announcement from Haizheng Pharmaceutical indicates that the EU has lifted the GMP non-compliance status for the company's Taizhou factory, which is expected to positively impact the company's product sales in the EU and other markets [1] Group 1: Company Impact - The lifting of the GMP non-compliance status is a significant development for Haizheng Pharmaceutical, as it allows for the resumption of product sales to the EU market [1] - The company may experience an increase in market opportunities due to the restored compliance status, although the recovery may be influenced by various factors such as market environment and sales channels [1] Group 2: Industry Context - The pharmaceutical industry is characterized by strict regulatory compliance, and the EU market's recovery may face uncertainties despite the positive news regarding GMP compliance [1]